Companies / Aspisafe Solutions

Medical device company profile

Aspisafe Solutions

Brooklyn medical device company offering feeding-tube securement devices and developing enteral feeding and personalized nutrition technologies.

Medical Device ManufacturerGastroenterology & Digestive HealthGastroenterology

Headquarters🇺🇸Brooklyn, New York, United States

Founded2017

Commercial statusCommercially availableNG Guard and NG Lock commercially offered; NG+ and SAMMY market status unconfirmed.

Employees2–10 ^[3]LinkedIn company-size range · Checked 2026-11-02

Estimated revenueNot confirmed

Official websitewww.aspisafesolutions.com ↗

Company overview

Aspisafe Solutions is a Brooklyn, New York medical device company founded in 2017 and led by founder and CEO Talal Sharaiha. Its focus is feeding-tube securement and nutrition management for hospitalized patients, including those receiving intensive care.

The company commercially offers NG Guard for nasogastric tube securement and NG Lock for feeding-tube securement in intubated patients. Its manufacturer brochure provides ordering details for both devices, while MAGNET Group lists an NG Guard purchasing agreement.

Its broader programs include NG+, a balloon-based feeding-tube system intended to limit reflux, and SAMMY, a nutrition management concept combining indirect calorimetry with feeding delivery. Their current commercial availability and regulatory status remain unconfirmed.

^{[1][2][3][4][6]}

Leadership

6 people

Talal SharaihaFounder & Chief Executive Officer ^[2]

Stephane GobronChief Technology Officer ^[2]

Patrick HoweChief Commercial Officer ^[2]

Megan PalatoClinical Specialist ^[2]

Nikhil KatreLead Engineer, NG Guard & Aspisafe NG+ ^[2]

Nam TrinhDirector, Quality & Regulatory Affairs ^[2]

Products & regulatory status How does MedTechIndex get this information?

Summary

NG Guard and NG Lock are commercially offered securement devices, with stock numbers and ordering quantities in the manufacturer’s brochure. MAGNET Group separately lists an NG Guard purchasing agreement through October 2027. ^[6][4]

Aspisafe also presents NG+ and SAMMY as product programs. A 2024 study evaluated Aspisafe NG and NG+ esophageal balloon pressure measurements in a biomechanical model; it was not a clinical trial demonstrating prevention of aspiration pneumonia. Current marketing authorization and commercial availability for NG+ and SAMMY remain unconfirmed. ^[1][5]

Regulatory snapshot How to read this snapshot

U.S. FDA

—
510(k) clearances: —
De Novo grants: —
PMA approvals: —
Recall events

Latest recorded source review: 2026-11-02.

Scope: selected product families.

Commercial portfolio snapshot

Documented commercial product families.

Nasogastric tube securement

NG Guard ↗

External securement device for nasogastric tubes, combining a head strap, foam support and tube-holding bracket. The manufacturer lists stock number 4100 in boxes of 12; MAGNET Group lists an NG Guard purchasing agreement. ^[1][6][4]

Commercially offered · securement device

Orogastric tube securement

NG Lock ↗

Securement component for orogastric or nasogastric tubes in intubated patients, designed to attach to an endotracheal tube securement device. The brochure specifies feeding-tube sizes 10–18F and stock number 4200 in boxes of 25. ^[1][6]

Commercially offered · securement device

Commercial development

Feeding-tube research program

Aspisafe NG+ ↗

Feeding-tube system with esophageal and gastric balloons designed for sequential inflation to limit reflux. Published bench research evaluated pressure-measurement performance; clinical aspiration-prevention efficacy and current commercial status are not established. ^[1][5]

Pipeline program · commercial status unconfirmed

Nutrition management program

SAMMY ↗

Company-described nutrition management system combining indirect calorimetry with a feeding pump to match caloric delivery to measured energy requirements. Current development stage, commercial availability and regulatory authorization remain unconfirmed. ^[1]

Pipeline program · commercial status unconfirmed